BDRX on Nasdaq
Biodexa Pharmaceuticals Plc
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | 381.0K GBP | ||
| Other income | 152.0K GBP | 31.0K GBP | 14.0K GBP |
| Research and development costs | -4.0M GBP | -5.4M GBP | -4.1M GBP |
| Administrative costs | -4.8M GBP | -3.8M GBP | -4.3M GBP |
| Loss from operations | -8.6M GBP | -9.2M GBP | -8.0M GBP |
| Finance income | 2.4M GBP | 3.4M GBP | 570.0K GBP |
| Finance expense | -229.0K GBP | -165.0K GBP | -41.0K GBP |
| Loss before tax | -6.5M GBP | -6.0M GBP | -7.5M GBP |
| Taxation | 105.0K GBP | 250.0K GBP | 406.0K GBP |
| Loss for the year attributable to the owners of the parent | -6.4M GBP | -5.7M GBP | -7.1M GBP |
| Exchange gains arising on translation of foreign operations | 3.0K GBP | ||
| Total other comprehensive income net of tax | 3.0K GBP | ||
| Total comprehensive loss attributable to the owners of the parent | -6.4M GBP | -5.7M GBP | -7.1M GBP |
| Basic loss perordinary share | -0.00 GBP | -0.00 GBP | -0.02 GBP |
| Diluted loss perordinary share | -0.00 GBP | -0.00 GBP | -0.02 GBP |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Property, plant and equipment | 91.0K GBP | 324.0K GBP | 571.0K GBP |
| Intangible assets | 5.6M GBP | 5.6M GBP | 2.9M GBP |
| Total Non-Current Assets | 5.7M GBP | 6.0M GBP | 3.5M GBP |
| Trade and other receivables | 3.8M GBP | 6.6M GBP | 637.0K GBP |
| Current taxation receivable | 123.0K GBP | 573.0K GBP | 422.0K GBP |
| Cash and cash equivalents | 8.5M GBP | 1.7M GBP | 6.0M GBP |
| Total Current Assets | 12.4M GBP | 8.8M GBP | 7.0M GBP |
| Total assets | 18.2M GBP | 14.8M GBP | 10.5M GBP |
| Deferred consideration | 645.0K GBP | 1.3M GBP | |
| Borrowings | 118.0K GBP | 295.0K GBP | |
| Total Non-Current Liabilities | 645.0K GBP | 1.4M GBP | 295.0K GBP |
| Trade and other payables | 2.6M GBP | 3.5M GBP | 1.2M GBP |
| Deferred consideration | 563.0K GBP | 538.0K GBP | |
| Borrowings | 61.0K GBP | 609.0K GBP | 169.0K GBP |
| Derivative financial liability | 2.9M GBP | 383.0K GBP | 4.2M GBP |
| Total Current liabilities | 6.1M GBP | 5.0M GBP | 5.6M GBP |
| Total liabilities | 6.8M GBP | 6.5M GBP | 5.9M GBP |
| Share capital | 14.1M GBP | 11.7M GBP | 6.3M GBP |
| Share premium | 98.9M GBP | 93.1M GBP | 86.7M GBP |
| Merger reserve | 53.0M GBP | 53.0M GBP | 53.0M GBP |
| Warrant reserve | 1.2M GBP | 894.0K GBP | 3.5M GBP |
| Foreign exchange reserve | 3.0K GBP | ||
| Accumulated deficit | -155.8M GBP | -150.4M GBP | -144.8M GBP |
| Total equity | 11.4M GBP | 8.3M GBP | 4.7M GBP |
| Total equity and liabilities | 18.2M GBP | 14.8M GBP | 10.5M GBP |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Loss for the year | -6.4M GBP | -5.7M GBP | -7.1M GBP |
| Depreciation of property, plant and equipment | 52.0K GBP | 117.0K GBP | 143.0K GBP |
| Depreciation of right of use asset | 136.0K GBP | 135.0K GBP | 137.0K GBP |
| Amortisation of intangible fixed assets | 1.0K GBP | 2.0K GBP | 3.0K GBP |
| Loss on disposal of property, plant and equipment | 29.0K GBP | 4.0K GBP | 2.0K GBP |
| Impairment of loan | 79.0K GBP | ||
| Impairment of ELOC upfront fee | 373.0K GBP | ||
| Finance income | -2.4M GBP | -3.4M GBP | -570.0K GBP |
| Finance expense | 229.0K GBP | 165.0K GBP | 41.0K GBP |
| Share-based payment charge | 170.0K GBP | 283.0K GBP | 28.0K GBP |
| Taxation | -105.0K GBP | -250.0K GBP | -406.0K GBP |
| Foreign exchange losses/(gains) | -130.0K GBP | 4.0K GBP | |
| Cash flows from operating activities before changes in working capital | -8.0M GBP | -8.7M GBP | -7.6M GBP |
| Decrease/(Increase) in trade and other receivables | 2.6M GBP | -6.0M GBP | 365.0K GBP |
| (Decrease)/Increase in trade and other payables | -913.0K GBP | 2.2M GBP | -207.0K GBP |
| (Decrease)/Increase in provisions | -207.0K GBP | ||
| Cash used in operations | -6.3M GBP | -12.4M GBP | -7.7M GBP |
| Taxes received | 707.0K GBP | 129.0K GBP | 845.0K GBP |
| Net cash used in operating activities | -5.6M GBP | -12.3M GBP | -6.8M GBP |
| Purchases of property, plant and equipment | -2.0K GBP | -9.0K GBP | -26.0K GBP |
| Proceeds from disposal of fixed assets | 18.0K GBP | 4.0K GBP | |
| Purchase of intangible asset/deferred consideration | -689.0K GBP | -765.0K GBP | -237.0K GBP |
| Loan granted | -79.0K GBP | ||
| Interest received | 90.0K GBP | 176.0K GBP | 73.0K GBP |
| Net cash (used in)/generated from investing activities | -583.0K GBP | -598.0K GBP | -265.0K GBP |
| Interest paid | -14.0K GBP | -13.0K GBP | |
| Amounts paid on lease liabilities | -246.0K GBP | -186.0K GBP | -188.0K GBP |
| (Repayment)/Proceeds from promissory note | -450.0K GBP | 431.0K GBP | |
| Share issues including warrants, net of costs | 13.7M GBP | 8.3M GBP | 10.4M GBP |
| Net cash generated from financing activities | 13.0M GBP | 8.6M GBP | 10.2M GBP |
| Net increase/(decrease) in cash and cash equivalents | 6.9M GBP | -4.3M GBP | 3.1M GBP |
Former names
- Midatech Pharma PlcJun 4, 2015 to Mar 27, 20232
Recent filings
- Oct 14, 2026424B3 333-299106
- Oct 14, 2026424B3 PROSPECTUS SUPPLEMENT NO. 5
- Oct 14, 2026424B3 333-281489
- Oct 14, 2026424B3 PROSPECTUS SUPPLEMENT NO. 5
- Oct 14, 2026424B3 333-284350 PROSPECTUS SUPPLEMENT NO. 5
- Oct 14, 2026424B3 333-297473
- Oct 14, 2026424B3 PROSPECTUS SUPPLEMENT NO. 5
- Oct 14, 2026424B3 333-279994
- Oct 14, 20266-K
- Oct 8, 20266-K
- Oct 6, 2026424B3
- Sep 30, 2026EFFECT
- Sep 24, 2026F-1 WARRANT INDUCEMENT
- Sep 15, 20266-K
- Sep 15, 2026424B3
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3